Which biosimilar trastuzumab medications have been FDA approved for the treatment of HER2-positive breast cancer?

Updated: May 14, 2019
  • Author: Maurie Markman, MD, MS; Chief Editor: Karl S Roth, MD  more...
  • Print


Since December 2017, the FDA has approved 4 biosimilars of trastuzumab (Herzuma, Ogivri, Ontruzant, Trazimera) to treat HER2-overexpressed breast cancer. All biosimilars of trastuzumab have demonstrated efficacies and safety outcomes similar to those of the standard trastuzumab. [25, 26, 27, 28]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!